Head-to-Head cancer drug showdown: which treatment helps patients live longer?
NCT ID NCT02684292
Summary
This study compared two different drugs for people whose Hodgkin lymphoma returned or didn't respond to previous treatment. Researchers tested whether pembrolizumab (an immunotherapy drug) worked better than brentuximab vedotin (a targeted therapy) at keeping the cancer from progressing and helping patients live longer. The trial involved 304 participants who received one of the two treatments for up to 35 cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.